Multi-target potentially antitumor agents for malignant melanoma: rational design, synthesis, and biological assays of novel benzofuroxan derivatives

• Grant number: 14/14267-1
• Support Opportunities: Scholarships in Brazil - Post-Doctoral
• Effective date (Start): February 01, 2015
• Effective date (End): January 31, 2019
• Field of knowledge: Health Sciences - Medicine
• Acordo de Cooperação: Coordination of Improvement of Higher Education Personnel (CAPES)
• Principal Investigator: Jose Alexandre Marzagão Barbuto
• Grantee: Salomão Dória Jorge
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated scholarship(s): 17/01265-9 - Multi-target potentially antitumor agents for malignant melanoma: rational design, synthesis, and biological assays of novel benzofuroxan derivatives, BE.EP.PD

Abstract

The study is based on previously findings observed for a series of substituted-[N'-(benzofuroxan-5-yl)methylene] benzohydrazides. These compounds, initially developed as anti-Trypanosoma cruzi agents, have shown potent cytotoxic effects against a variety of malignant tumor cells, that overexpressing MDMX protein. This protein is responsible for the deficiency of functional p53 in tumors such as melanoma, that even with wild type p53, this functionality has inhibited by MDMX. However, cancer is a multifactorial disease, which imposes the need to aggregate, in design of new drugs, different pharmacodynamic profiles capable of modulating distinct signaling pathways, in one molecule, creating drugs "multi-targets". Melanoma is the most aggressive form of skin cancer and it has been presented high resistance to many chemotherapy drugs therapeutically used, requiring the development of new therapeutic strategies. In this regard, the present proposal aims to identify antitumor drug candidates from the synthesis of a novel benzofuroxan-based library. Preliminary data obtained from lead compound, already indicate that, in addition to MDMX, BRAF protein (most promising therapeutic target in melanoma) is also affected in melanoma murine cell line B16F10. These observations indicate that these lead compound has potential to act on several tumor cell targets, suggesting that their use as structural template allied to the ligand-based drug design strategy aims the identification of novel analogs/derivatives with multi-target activity, therefore, with better probability of anticancer efficacy. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

MAMBELLI, LISLEY I.; TEIXEIRA, SARAH F.; JORGE, SALOMAO D.; KAWAMURA, BARBARA; MENEGUELO, RENATO; BARBUTO, JOSE A. M.; DE AZEVEDO, RICARDO A.; FERREIRA, ADILSON K.. Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model. BIOMEDICINE & PHARMACOTHERAPY, v. 103, p. 18-28, JUL 2018. (15/18528-7, 16/07519-0, 17/01265-9, 16/09392-7, 13/07273-2, 14/14267-1)

TEIXEIRA, SARAH FERNANDES; DE AZEVEDO, RICARDO ALEXANDRE; SILVA, ARTHUR CARVALHO; BRAGA, RODOLPHO CAMPOS; JORGE, SALOMAO DORIA; MARZAGAO BARBUTO, JOSE ALEXANDRE; ANDRADE, CAROLINA HORTA; FERREIRA, ADILSON KLEBER. Evaluation of cytotoxic effect of the combination of a pyridinyl carboxamide derivative and oxaliplatin on NCI-H1299 human non-small cell lung carcinoma cells. BIOMEDICINE & PHARMACOTHERAPY, v. 84, p. 1019-1028, DEC 2016. (16/05351-4, 09/54599-5, 13/05396-0, 15/18528-7, 14/07341-0, 14/24455-0, 13/07273-2, 14/14267-1)

FERREIRA, ADILSON KLEBER; MESQUITA PASQUALOTO, KERLY FERNANDA; KRUYT, FRANK A. E.; PALACE-BERL, FANNY; AZEVEDO, RICARDO ALEXANDRE; TURRA, KELY MEDEIROS; RODRIGUES, CECILIA PESSOA; FRANCO FERREIRA, ANA CAROLINA; CLAVIJO SALOMON, MARIA ALEJANDRA; DE SA JUNIOR, PAULO LUIZ; et al. BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. Toxicology and Applied Pharmacology, v. 295, p. 56-67, MAR 15 2016. (09/54599-5, 13/05396-0, 14/07341-0, 13/07273-2, 14/14267-1)